1. Venous Thromboembolism Prophylaxis Should Be Recommended for Antepartum Admissions and Cesarean Delivery if Age and Body Mass Index Are Greater Than 35.
- Author
-
Shields, Laurence E., Feldman, Daniele, Klein, Catherine, Foster, Mindy, and Lin, Stephanie
- Subjects
- *
THROMBOEMBOLISM risk factors , *CESAREAN section , *RISK assessment , *BODY mass index , *MATERNAL age , *PATIENTS , *VEINS , *HOSPITAL admission & discharge , *POSTNATAL care , *RETROSPECTIVE studies , *HOSPITALS , *MATERNAL mortality , *PRENATAL care , *DISEASES , *DRUG efficacy , *COMPRESSION garments , *BLOOD diseases , *QUALITY assurance , *NOSOLOGY , *DISEASE risk factors , *PREGNANCY ,THROMBOEMBOLISM prevention - Abstract
Objective Venous thromboembolism (VTE) is a major cause of maternal morbidity and mortality. Current expanded treatment recommendations result in the inclusion of a large percentage of the obstetric population, which has limited their adoption. The purpose of this study was to identify a population at high risk for VTE, with minimal impact on the number of patients that would qualify for expanded treatment. Study Design We performed a retrospective analysis of a large obstetric population. International Classification of Diseases, 10th Revsion (ICD-10) codes for VTE were used to identify patients presenting for obstetric or postpartum (PP) care from January 2016 to March 2018. The review focused on high-risk factors (history of VTE or high-risk thrombophilia), antepartum hospital admissions that were >72 hours in the previous 30 days, use of sequential compression devices, body mass index (BMI; kg/m 2), age, and mode of delivery. Pharmacologic treatment efficacy was set at 90, 75, or 50%. Results During the 27-month review period, there were 120,235 deliveries and 93 had a VTE event in the index pregnancy or within 4 weeks PP (7.7/10,000 births). A history of VTE or high-risk thrombophilia was seen in 25.8% of cases. Antepartum admission was noted in 40.9%, and the combination of cesarean delivery (CD) with age and BMI ≥35 (Age + BMI + CD) was noted in 17.3% of PP cases. Targeting these latter two groups for VTE prophylaxis with a 75% efficacy suggests that 34% of the VTE events would likely have been prevented while increasing the total population treated by approximately 2%. Conclusion Expanding pharmacologic prophylactical coverage to include an antepartum admission of >72 hours and those with Age + BMI + CD would result in about a one-third reduction in total VTE events with about 2% requiring treatment. These data support some of the suggested recommendations for expanded pharmacological deep venous thrombosis prophylaxis. Key Points CD, and BMI and age >35 are high-risk factors for VTE. Antepartum admission >72 hours is a high-risk factor for VTE. Targeting antepartum admissions, CD, and BMI and age >35 would reduce VTE events by about 33%. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF